M
any new drugs offer promise for cancer patients. Although some increase cure rates, 1,2 many recently approved drugs only increase survival by several months. 3, 4 Treatment decisions for patients can be difficult as these therapies are often associated with toxicities. Acquisition costs for new drugs exceed $5000 per month, making the decision more complex, as even patients with comprehensive insurance coverage can face high out-of-pocket costs. 5 The American Society of Clinical Oncology recommends that physicians discuss out-of-pocket costs with their patients. 6 However, many oncologists find these conversations difficult to initiate. 7 There is little information about how patients make trade-offs when choosing among treatments of differing efficacy, toxicity, and out-of-pocket cost. By giving patients "skin in the game," cost-sharing is intended to reduce unnecessary utilization of medical services. 8 However, these cost-sharing models assume that patients can make informed decisions about whether the treatment is worth the out-ofpocket cost. Further, in many cases cost-sharing is based on the cost of the drug and not its clinical indication or value.
Preferences can be defined as the value a patient places on the outcome (both good and bad) of each treatment alternative 9 and may differ on the basis of the clinical setting. For example, it is not known whether patients are willing to tolerate higher cost in the curative setting than in the noncurative setting.
Discrete choice experiments (DCEs) may be helpful in understanding decision trade-offs by clarifying the value an individual places on a treatment on the basis of its particular characteristics. DCEs are frequently used in marketing studies, but have also been used in health care policy on the basis of the premise that a service can be described by its attributes, and the extent to which a patient values a service depends on the perceived relative strength of these characteristics. 10, 11 Each attribute, such as copayment, is assigned a level (for example, $10, $50, or $100). Participants choose between different services (eg, treatments) that vary in the levels of the attributes of interest (eg, cost, efficacy, toxicity). They are presented multiple scenarios with treatments having different combinations of attribute levels. The preference for each attribute can be determined along with the individual characteristics that are associated with placing more or less weight on a given attribute.
In this study, we conducted DCEs to understand how patients choose among cancer treatments of varying efficacies, toxicities, and out-of-pocket costs. We then used latent class analysis (LCA) to identify subgroups of patients with specific preferences. The goal of this study was to understand whether patient characteristics affect these preferences and whether the clinical setting (curative vs. noncurative) itself influenced choice.
MATERIALS AND METHODS

Patients
Patients were recruited from Fox Chase Cancer Center, a National Cancer Institute designated Comprehensive Cancer Center in Philadelphia, PA, and from South Jersey Healthcare in Vineland, NJ, a community hospital serving rural Southern New Jersey. Patients were at least 18 years of age and diagnosed with cancer at least 6 months before initial contact. Those with metastatic disease were required to have a performance status of 0 or 1 (asymptomatic or minimally symptomatic). There were no restrictions on disease site, stage, time from original diagnosis, or prior treatment.
Potential participants were initially contacted by mail with a letter that described the study. They were given a response card in which they could (1) express interest in participating, (2) decline further contact, or (3) request further information. They were told that if they did not return the card they might be contacted about the study in person at the time of their next appointment. Patients were approached in person by trained research assistants. Those that provided written informed consent completed the study on a computer. They received a $20 gift card after completing the study. Patients were recruited between January 5, 2010 and September 1, 2011. Institutional Review Boards at both sites approved the study.
Survey Instrument
Patients provided demographic data including age, education, annual household income, and employment status. They also provided cancer history including year of diagnosis, primary site, and presence of metastases.
We assessed numeracy using the Subjective Numeracy Scale 12 and optimism using the Life Orientation Test-Revised. 13 We asked patients to describe their health care cost concerns (using a 5-point Likert scale): 
Attribute Levels
Attribute levels are shown in Table 1 . Within each scenario, there were 2 levels for efficacy and toxicity, and 4 levels of potential out-of-pocket costs. As the magnitudes of cost levels varied between scenarios, we reported cost-level differences. For example, patients who were presented with the highest (level 4) and lowest (level 1) choices had a 3-level difference. Patients who were presented with level 4 and level 2 (or levels 3 and 1) choices had a 2-level difference.
Scenarios were pilot tested in 24 patients and refined. In the final study, each patient received 2 of the 3 scenarios. They were given 9 discrete choice pairs within each scenario. Sawtooth software (Orem, UT) was used to generate the choice pairs.
Data Analyses
We analyzed this study in 2 parts. First, we sought to understand what influenced a patient to pick one treatment over the other. We used a Bradley-Terry logistic model to investigate the characteristics that drove decisions about choosing a scenario. 14 To account for correlated data, we estimated the models using Generalized Estimating Equations. 15 The correlated data resulted from individuals making repeated choices concerning scenarios. In these models, positive ( > 0) regression coefficients indicated a preference for higher levels of specific attributes (ie, greater survival). A negative coefficient indicated preference for the lower level (ie, lower toxicity).
We then sought to understand whether there were specific patient characteristics that predicted preferences for treatment attributes within individual scenarios. For example, we sought to understand what characteristics would predict a preference for low out-of-pocket cost treatments in the metastatic scenario. We used LCA to investigate whether groups of individuals could be identified on the basis of response patterns. [16] [17] [18] [19] [20] [21] This is similar to cluster analytic methods, but more suited for binary data. LCA assumes that the population from which the sample is drawn consists of underlying classes of individuals who can be grouped according to their choice patterns. The model estimates the proportion of patients within each class, and then, within each class, it estimates the proportion of patients choosing a scenario with a certain characteristic (eg, higher survival).
According to likelihood ratio tests, the 3-class model provided the best fit in adjuvant scenario 1 and the palliative scenario. In adjuvant scenario 2, a 4-class model slightly outperformed a 3-class model. However, the fit for the 3-class model was close and more easily interpretable.
Finally, after estimating our latent class models, we estimated the probabilities of class membership for patients. We used logistic regression of the patients' characteristics (eg, education) with each patient's probabilities of belonging to the respective classes as covariates to investigate whether differences in characteristics among the 3 classes were statistically significant.
We used STATA 12.0 and its glamm macro (StataCorp, College Station, TX) for all analyses.
RESULTS
We approached 584 patients in person. Of these, 400 signed informed consent and completed the main study. Fourteen agreed to participate but did not have time to compete the study; 167 declined. Three could not read English and were not enrolled. In total, 2374, 2392, and 2364 choice pairs were completed for scenarios 1, 2, and 3, respectively.
Patient characteristics and responses to the cost concern questions are shown in Table 2 . The median age was 61 years (range, 27-90 y). Less than half of the group had a college education. Forty-four percent reported an annual household income of <$60,000 per year. The most common primary sites of disease reported by participants were breast (35%) and genitourinary tract (16.5%). Twenty-seven percent reported having metastatic disease. Fifty percent were diagnosed in 2006 or later. Twenty-five percent were recruited from the community site.
Patients recruited from the academic center reported a higher educational level and household income than patients at the community hospital. In addition, they had greater numeracy skills (P < 0.05). However, there was no difference between recruitment sites in the percentage of patients reporting concerns about the present or future treatment costs or levels of optimism (data not shown).
Patient Preferences
In all 3 scenarios, patients were more likely to choose the option that favored higher survival. In each scenario, patients expressed a strong preference to avoid 1 of 2 toxicities, namely, severe heart failure, neuropathy and bleeding, and a less pronounced, but statistically significant, preference to avoid the other toxicities, such as any heart failure, nausea, and fatigue.
In addition, in all 3 scenarios patients were less likely to choose the most expensive treatment (3-level difference in cost). However, the strength of this preference was lower than the preference for survival or lower toxicity. With the exception of adjuvant scenario 2, they were also less likely to choose a 2-level difference in cost (see Figure, Supplemental Digital Content 2, http://links.lww.com/MLR/A525, which demonstrates the results of our multivariable analysis including all the treatment variables).
Latent Class Assignment
If a patient were choosing randomly, he or she would have a 50% chance of choosing 1 of the 2 options. However, we identified 3 "latent classes" (Table 3) of patients who appeared to demonstrate dominant preferences for either: (1) low out-of-pocket cost; (2) longer survival; or (3) low toxicity. In adjuvant scenario 1, 99.8% of patients in class A would choose the lower-cost treatment when offered a choice between 2 treatments with a large cost difference (3-level), even if the alternative offered improved survival or toxicity. Class A was sensitive to more modest cost differences as well; even if the cost difference was only 1-level, 89.6% would still choose the lowest-cost treatment. This demonstrates that preference for low out-of-pocket cost was the dominant preference within this latent class. However the distribution of choices for the survival and toxicity attributes were approximately 50%/50%, consistent with being chosen randomly. Conversely, in class B, the latent class that favors survival, 98.3% would choose the treatment with greater survival.
Within each scenario, class A favored low out-ofpocket cost treatments when presented with a 2-level cost difference. Across all 3 scenarios, >94% would choose the lower-cost treatment even if the more costly treatment offered improved survival or toxicity.
Other patients had similarly strong preferences for improved survival; in class B, >92% of patients would choose the treatment with longer survival, even if it was more costly or toxic.
Class C in each scenario favored low toxicity. In this class, 70%-80% of patients chose the treatment with low toxicity, regardless of whether the alternative treatment offered greater survival and/or lower cost.
Association Between Latent Class and Patient Characteristics
Within each scenario, we then measured the association between patient characteristics and latent class (Table 4) . These are divided into sections, which evaluate individual characteristics within scenarios.
We found statistically significant associations between certain sociodemographic characteristics and latent class. In all scenarios, patients with lower income were less likely than those with higher income to be in the class that focused on survival. For example, in adjuvant scenario 1, patients with an annual household income <$60,000 were less likely to be in the class that favored survival (class B) compared with those with a higher income (10.7% vs. 24.4%), but were more likely to be in the class (class A) that favored low outof-pocket cost (33.6% vs. 23.1%). In adjuvant scenario 1, patients who were not working (compared with employed, homemaker, or retired) were less likely to be in the class that favored survival (class B) (3.9% vs. 17.7%). Education was predictive of class assignment in adjuvant scenario 2 and the palliative scenario (P < 0.05 for all comparisons). We also identified other patient characteristics associated with latent class (Table 5 ). In all 3 scenarios, greater numeracy was associated with being in the class that favored survival (class B). In the palliative scenario, greater optimism and younger age was also associated with being in the class that favored survival (class B). Cost concerns were associated with class assignment in adjuvant scenario 2 and the palliative scenario. For example, in the palliative scenario, patients who disagreed with the statement "I am confident that my insurance will cover health care costs in the future" were more likely to be in the class that preferred low out-of-pocket cost (class A). There was no association between cost concerns, optimism, or age and class in adjuvant scenario 1.
There was no association between year of diagnosis, site of primary tumor, presence of metastatic disease, or hospital sites and latent class assignment.
DISCUSSION
In this study, we used DCE in a heterogenous group of cancer patients to understand the trade-offs patients may make when considering choices among treatments with varying efficacies, toxicities, and out-of-pocket costs in both the curative and noncurative setting. We found that patients expressed specific preferences for survival and low toxicity, and preference to avoid very large (3-level) cost differences. They appeared to be less averse to moderate (2-level) differences in cost. Patient characteristics also predicted preference for treatment efficacy, toxicity, and out-of-pocket cost. In all 3 scenarios, patients of higher socioeconomic status (SES) were more likely to focus on survival, whereas others appeared more willing to trade off survival for decreased out-of-pocket cost and toxicity. In the palliative scenario and adjuvant scenario 2, patients who expressed concerns about cost were more likely to choose the treatment with lower out-of-pocket costs, even if it came at the expense of worse survival or higher toxicity. These findings are important for several reasons. Patients are frequently faced with complex treatment choices. Although physicians may provide guidance, there are some decisions that are preference sensitive. For example, a patient with young children may be more willing to tolerate toxic treatment, 22 whereas a patient with competing comorbidities may be more averse to toxicity, particularly for a noncurative therapy.
Decision-making is further complicated by high outof-pocket costs. Many prescription plans place oral anticancer medications on the "top tier," which can result in high copayments. How these costs influence patients' treatment decisions and subsequent clinical outcomes is not known. A study of commercial claims found cancer patients to be "cost-insensitive," and reported that cancer patients do not decrease their utilization of oral anticancer medications in response to higher out-of-pocket cost. 23 This could be due to the "hope" that patients assign to novel therapies for advanced cancer, for which many patients are willing to bear high costs. 24 However, other studies have demonstrated that patients may be cost-sensitive. An analysis of a commercially insured population found that patients with early-stage breast cancer who face high copayments for adjuvant hormonal therapy are less likely to be compliant with therapy. 25 Other studies have found similar inverse relationships between cost-sharing and cancer medication adherence. 26 In a study of 254 cancer patients, of whom 75% applied to a national copayment assistance foundation, 20% took less than the prescribed amount, 19% partially filled the prescriptions, and 24% avoided filling them. 27 The greater sensitivity to out-of-pocket treatment cost among patients of lower SES (income, education, employment status) is especially concerning given the fact that almost all of these patients were insured and had already established care with a medical or surgical oncologist. Although we do not have data about the extent of out-of-pocket costs they have already faced, 22% reported that their family had already made a sacrifice to pay for their care, suggesting that they felt some level of distress. In a previous study that measured willingness-to-pay of cancer patients in the adjuvant and palliative setting, those who reported making sacrifices were less likely to be willing to pay high copayments for palliative treatment. 28 In this study, patients who reported concerns about present and future costs were more likely to be in the group that favored low out-of-pocket cost.
Relationships between cost concerns and latent class were only present in adjuvant scenario 2 and the palliative scenario. It is possible that in adjuvant scenario 1, the survival benefit (13%) was significant enough to outweigh other concerns. However, when the benefit was more modest (in adjuvant scenario 2 and the palliative scenario), patients were more likely to weigh other factors (such as cost concerns) against the smaller benefit.
Our results should be evaluated within the context of several study limitations. We used hypothetical scenarios that did not identify the drug or disease. We do not know whether patients would respond in the same way when facing real-life decisions. However, DCE and other conjoint analysis methods have been used to identify preferences for health care 10, 11 and to understand clinical decision-making in other cancer settings. 29, 30 In addition, even in the hypothetical scenarios that did not require patients to actually spend their own money, SES and self-reported concerns about treatment costs were predictive of patient preferences. This also suggests that patients were answering in a manner consistent with their true concerns, preferences, and ability to pay.
In addition, 75% of our patients were enrolled from an academic hospital. We attempted to increase the generalizability by enrolling patients from a community hospital. As the patients at the academic hospital were more affluent and well educated than the patients in the community hospital, if we increased the number of patients accrued from the community hospital, we might have observed even more pronounced differences with regard to SES. Another limitation is that our study was cross-sectional. Clinical status might affect preferences. It is possible that patients who were diagnosed a longer time ago may have different preferences than someone who is currently undergoing treatment. However, we found no difference in preferences when controlling for the presence of metastatic disease or year of diagnosis. This should be studied in greater detail, particularly as patients may be treated with multiple lines of therapy, which may further strain family resources. In addition, we used a convenient sample of patients. It is possible that patients who agreed to participate may have had different preferences than those who declined.
Our findings may have clinical and policy implications. As increased emphasis is placed on preferencesensitive decisions and patient-centered outcomes, 31, 32 it is important to recognize that out-of-pocket costs may be an important component of patients' preferences. Physicians and other health care providers need to become more adept at discussing these cost-related concerns with patients and their families. They should be encouraged to refer them to appropriate resources including social workers and financial counselors. As patients who decline adjuvant therapy are at greater risk for relapse and for incurring further treatment costs for metastatic disease, payers may want to consider programs that reduce or eliminate out-of-pocket costs that serve as a barrier to care from high-value treatment. 33 In summary, even among insured patients, SES was highly predictive of treatment preference, with patients of higher SES being more likely to focus on survival when making decisions. Patients of lower SES may be more likely to avoid high out-of-pocket cost treatments regardless of efficacy or toxicity. Patients who already cite concerns about costs may be more likely to decline treatment that is more effective but have higher out-of-pocket costs. As payers increasingly shift costs to patients, the benefits of cost-sharing in reducing unnecessary utilization of health care services need to be balanced against the unintended consequence of potentially increasing disparities in care.
